Day: October 26, 2023

Global Phase 1/2 CHORD trial investigating otoferlin gene therapy (DB-OTO) represents Regeneron’s first auditory program and is currently enrolling patients DB-OTO is part of a growing pipeline of genetic medicines for hearing loss and other therapeutic areas that are being advanced by the company TARRYTOWN, N.Y., Oct. 26, 2023 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced preliminary, positive safety and efficacy results from the first patient (

ST. PETERSBURG, Fla., Oct. 26, 2023 (GLOBE NEWSWIRE) — BayFirst Financial Corp. (NASDAQ: BAFN) (“BayFirst” or the “Company”), parent company of BayFirst National Bank (the “Bank”) today reported net income of $1.9 million, or $0.41 per diluted common share, for the third quarter of 2023 compared to $1.4 million, or $0.29 per diluted common share, in the second quarter of 2023. Net income from continuing operations was $2.0 million for the third quarter of 2023, compared to net income from continuing operations of $1.4 million in the second quarter of 2023 and $3.1 million in the third quarter of 2022. The increase in earnings from continuing operations during the third quarter of 2023, as compared to the second quarter of 2023, was primarily the result of higher noninterest income of $3.7 million, or 34.2%, substantially attributable...

MILWAUKEE, Wis., Oct. 26, 2023 (GLOBE NEWSWIRE) — STRATTEC SECURITY CORPORATION (“STRATTEC” or the “Company”) (NASDAQ:STRT) today reported operating results for the fiscal first quarter ended October 1, 2023. Net sales for the first quarter ended October 1, 2023 were $135.4 million, compared to net sales of $120.4 million for the first quarter ended October 2, 2022. Net income was $4.2 million in the current year first quarter, compared to net income of $125,000 in the prior year first quarter. Diluted earnings per share for the current year quarter were $1.05 and for the prior year first quarter were $0.03. Net sales to each of our customers in the current year quarter and prior year quarter were as follows (in thousands):  Three Months Ended    October 1, 2023     October 2, 2022General Motors Company $ 40,505   $ 38,150Stellantis   27,297     17,155Ford...

MP0317 Phase 1 dose escalation recruitment completed in patients with advanced solid tumors; updated clinical results to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in November 2023MP0533 Phase 1/2a recruitment in r/r AML patients proceeding as planned with initial data expected at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2023Radio-DARPin Therapy (RDT) platform continues to progress, supporting the expansion of target universe accessible by radiotherapy; recent advances presented at the European Association of Nuclear Medicine (EANM) Annual Meeting in September 2023Funded well into 2026, with cash and cash equivalents of CHF 207 million as of September 30, 2023ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) —...

VANCOUVER, Wash., Oct. 26, 2023 (GLOBE NEWSWIRE) — Riverview Bancorp, Inc. (Nasdaq GSM: RVSB) (“Riverview” or the “Company”) today reported earnings of $2.5 million, or $0.12 per diluted share, in the second fiscal quarter ended September 30, 2023, compared to $2.8 million, or $0.13 per diluted share, in the first fiscal quarter ended June 30, 2023, and $5.2 million, or $0.24 per diluted share, in the second fiscal quarter a year ago. In the first six months of fiscal 2024, net income was $5.3 million, or $0.25 per diluted share, compared to $9.8 million, or $0.45 per diluted share, in the first six months of fiscal 2023. “Our operating results for the second fiscal quarter of 2024 remained sound, as we continue to be impacted by higher interest expense on deposits and borrowings,” stated Dan Cox, Chief Operating Officer, Acting...

        NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. TORONTO, Oct. 26, 2023 (GLOBE NEWSWIRE) — FRNT Financial Inc. (TSXV:FRNT) (OTCQB:FRFLF) (FSE:XZ3) (“FRNT” or the “Company”); an institutional capital markets and advisory platform focused on digital assets, is pleased to announce the voting results from the Company’s Annual General Meeting of the Shareholders (the “Meeting”) held on October 25, 2023. A total of 21,410,863 common shares were voted, representing the votes attached to 60.97% of all outstanding common shares. All matters submitted to shareholders for approval as set out in the Company’s Notice of Meeting and Information Circular (the “Circular”), both dated September 19, 2023, were approved by the requisite majority of votes cast at the Meeting. Election of DirectorsEach...

AGAMREE® Indicated for the Treatment of Duchenne Muscular Dystrophy for Patients Aged Two Years and Older Catalyst Holds the Exclusive North American License to Commercialize AGAMREE (vamorolone) for Duchenne Muscular Dystrophy and Other Potential Indications Novel Corticosteroid With Favorable Side Effect Profile Catalyst Expects to Commercially Launch AGAMREE in Q1 2024 AGAMREE Comprehensive Patient Assistance Program to Help Ensure Affordable Access for All DMD Patients Upon Commercial Launch CORAL GABLES, Fla., Oct. 26, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX) today reported that Santhera Pharmaceuticals (“Santhera”) has obtained U.S. Food and Drug Administration (“FDA”) approval for AGAMREE® (vamorolone) oral suspension...

TORONTO, Oct. 26, 2023 (GLOBE NEWSWIRE) — ApartmentLove Inc. (CSE: APLV) (OTCQB: APMLF) (“ApartmentLove” or the “Company), a leading provider of online home, apartment, and vacation rental marketing services to property managers, owners, renters, and vacationers from around the world has decided not to proceed with two previously announced transactions, the first being the proposed acquisition of certain assets of Traffic2Revenue, Inc., a Florida-based internet marketing company, the second being the proposed acquisition of the assets of a luxury Internet listing real estate site. In its review, management noted material inconsistencies with the due diligence materials produced by the vendors of each respective proposed acquisition. These transactions were announced in press releases dated October 28, 2021, and...